Toll Free: 1-888-928-9744
Published: Apr, 2014 | Pages:
27 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
CardioVascular BioTherapeutics, Inc. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'CardioVascular BioTherapeutics, Inc. - Product Pipeline Review - 2014', provides an overview of the CardioVascular BioTherapeutics, Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of CardioVascular BioTherapeutics, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of CardioVascular BioTherapeutics, Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of CardioVascular BioTherapeutics, Inc.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the CardioVascular BioTherapeutics, Inc.'s pipeline products Reasons to buy - Evaluate CardioVascular BioTherapeutics, Inc.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of CardioVascular BioTherapeutics, Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the CardioVascular BioTherapeutics, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of CardioVascular BioTherapeutics, Inc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of CardioVascular BioTherapeutics, Inc. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of CardioVascular BioTherapeutics, Inc. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 3 List of Figures 3 CardioVascular BioTherapeutics, Inc. Snapshot 4 CardioVascular BioTherapeutics, Inc. Overview 4 Key Information 4 Key Facts 4 CardioVascular BioTherapeutics, Inc. - Research and Development Overview 5 Key Therapeutic Areas 5 CardioVascular BioTherapeutics, Inc. - Pipeline Review 7 Pipeline Products by Stage of Development 7 Pipeline Products - Monotherapy 8 CardioVascular BioTherapeutics, Inc. - Pipeline Products Glance 9 CardioVascular BioTherapeutics, Inc. - Clinical Stage Pipeline Products 9 Phase II Products/Combination Treatment Modalities 9 Phase I Products/Combination Treatment Modalities 10 CardioVascular BioTherapeutics, Inc. - Drug Profiles 11 CVBT-141A 11 Product Description 11 Mechanism of Action 11 R&D Progress 11 CVBT-141B 12 Product Description 12 Mechanism of Action 12 R&D Progress 12 CVBT-141H 14 Product Description 14 Mechanism of Action 14 R&D Progress 14 CVBT-141C 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 CardioVascular BioTherapeutics, Inc. - Pipeline Analysis 17 CardioVascular BioTherapeutics, Inc. - Pipeline Products by Target 17 CardioVascular BioTherapeutics, Inc. - Pipeline Products by Route of Administration 18 CardioVascular BioTherapeutics, Inc. - Pipeline Products by Molecule Type 19 CardioVascular BioTherapeutics, Inc. - Pipeline Products by Mechanism of Action 20 CardioVascular BioTherapeutics, Inc. - Recent Pipeline Updates 21 CardioVascular BioTherapeutics, Inc. - Dormant Projects 22 CardioVascular BioTherapeutics, Inc. - Discontinued Pipeline Products 23 Discontinued Pipeline Product Profiles 23 CVBT-141E 23 CardioVascular BioTherapeutics, Inc. - Company Statement 24 CardioVascular BioTherapeutics, Inc. - Locations And Subsidiaries 25 Head Office 25 Appendix 26 Methodology 26 Coverage 26 Secondary Research 26 Primary Research 26 Expert Panel Validation 26 Contact Us 27 Disclaimer 27
List of Tables CardioVascular BioTherapeutics, Inc., Key Information 4 CardioVascular BioTherapeutics, Inc., Key Facts 4 CardioVascular BioTherapeutics, Inc. - Pipeline by Indication, 2014 6 CardioVascular BioTherapeutics, Inc. - Pipeline by Stage of Development, 2014 7 CardioVascular BioTherapeutics, Inc. - Monotherapy Products in Pipeline, 2014 8 CardioVascular BioTherapeutics, Inc. - Phase II, 2014 9 CardioVascular BioTherapeutics, Inc. - Phase I, 2014 10 CardioVascular BioTherapeutics, Inc. - Pipeline by Target, 2014 17 CardioVascular BioTherapeutics, Inc. - Pipeline by Route of Administration, 2014 18 CardioVascular BioTherapeutics, Inc. - Pipeline by Molecule Type, 2014 19 CardioVascular BioTherapeutics, Inc. - Pipeline Products by Mechanism of Action, 2014 20 CardioVascular BioTherapeutics, Inc. - Recent Pipeline Updates, 2014 21 CardioVascular BioTherapeutics, Inc. - Dormant Developmental Projects,2014 22 CardioVascular BioTherapeutics, Inc. - Discontinued Pipeline Products, 2014 23
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.